In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …

Abstract PD-1/PD-L1 checkpoint blockades have achieved significant progress in several
kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line …

Background Immunosuppressive microenvironment is a major cause of immunotherapeutic
resistance in glioma. In addition to secreting compounds, tumor cells under programmed cell …

Purpose: Glioma tissues consist of not only glioma cells but also glioma-associated
nontumor cells, such as stromal cells and immune cells. These nontumor cells dilute the …

Objective Despite several clinicopathological factors being integrated as prognostic
biomarkers, the individual variants and risk stratification have not been fully elucidated in …

Gliomas are the most common and lethal intracranial tumours. RNA sequencing
technologies and advanced data analyses recently enabled the characterization of …

The Glioblastoma (GBM) immune microenvironment plays a critical role in tumor
development, progression, and prognosis. A comprehensive understanding of the intricate …

ACT001, which is derived from an ancient anti-inflammatory drug, has been shown to cross
the blood-brain barrier in preclinical studies and has demonstrated anti-glioblastoma (GBM) …

Background: Bromodomain and extra-terminal domain (BET) inhibitors have shown
profound efficacy against hematologic malignancies and solid tumors in preclinical studies …

Background Glioblastomas are the most common and lethal primary brain tumors. Microglia,
the resident immune cells of the brain, survey their environment and respond to pathogens …